TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β‐catenin/MYC axis
Abstract Background Enzalutamide resistance in advanced prostate cancer often leads to treatment‐induced neuroendocrine prostate cancer (t‐NEPC), characterized by aggressive lineage plasticity. The molecular regulators governing neuroendocrine differentiation and phenotypic transition are not well understood. Here, we...